Lung cancer care in Victoria
|
|
|
- Amber Mitchell
- 6 years ago
- Views:
Transcription
1 Lung cancer care in Victoria Identifying opportunities for improvement Prof David Ball
2 In this presentation Incidence and survival The lung cancer population at presentation Care pattern and variation across Victoria - Diagnosis, staging & treatment planning - Treatment (surgery, chemotherapy &radiotherapy) - Supportive and palliative care
3 Lung cancer optimal care pathway Prevention and early detection Presentation, initial investigations and referrals Diagnosis, staging and treatment planning Treatment Care after initial treatment and recovery Managing recurrent and residual disease End-of-life care
4 Lung cancer optimal care pathway Prevention and early detection Presentation, initial investigations and referrals Diagnosis, staging and treatment planning Treatment Care after initial treatment and recovery Managing recurrent and residual disease End-of-life care
5 Sources of data to describe current practice Victorian Cancer Registry Linked data set Victorian Admitted Episode Dataset Victorian Patterns of Care (POC) study 2003 Prevention and early detection Presentation, initial investigations and referrals Diagnosis, staging and treatment planning Treatment Care after initial treatment and recovery Managing recurrent and residual disease End-of-life care DH Cancer Performance Indicator Audit Victorian Radiotherapy Minimum Dataset Victorian Lung Cancer Registry
6 About linked data Links Victorian Cancer Registry with hospital activity data Ability to track each patient across Victorian public and private health services Allows identification of admitted lung cancer cases confirmed by the VCR Allows mapping of the patient s pathway Plan to include radiotherapy data
7 Data analysis Limitations of the linked VCR/VAED data set: Hume region activity data for patients treated at Albury Wodonga Health Albury Campus is not reported to the VAED or the VCR, and was not available for analysis. Staging is not currently available for lung cancer Observed differences could be due to the lung patient disease characteristics such as staging
8 Lung cancer incidence and survival in Victoria
9 Trends in incidence and mortality Victoria Incidence Mortality MALE Incidence Mortality FEMALE Source: Victorian Cancer Registry (VCR) Nov 2014
10 Lung cancer (C33-34) relative 5-year survival over time For time period the 5 year survival was at 15% Year Survival Percentage p< Period Source: VCR 2012 Cancer Survival Victoria
11 Lung cancer survival, Victoria survival by age group, year relative survival (%) % 23% 20% 17% 9% 0 < Age group at diagnosis Source: Victorian Cancer Registry Nov 2014
12 Integrated Cancer Services (ICS) & Cancer Centres Loddon Mallee ICS Bendigo Regional Cancer Centre Albury Wodonga Regional Cancer Centre Grampians ICS Hume ICS Gippsland ICS Barwon South Western ICS Ballarat Regional Cancer Centre Andrew Love Barwon Regional Cancer Centre Gippsland Regional Cancer Centre Olivia Newton John Cancer and Wellness Centre Western Central MICS North Eastern MICS Victorian Comprehensive Cancer Centre Southern MICS Monash Comprehensive Cancer Consortium
13 Lung cancer 5 year incidence numbers year incidence 4,000 3,442 3,500 3,000 2,697 2,413 2,500 2,000 1,500 1, , Barwon Gippsland Grampians Hume Loddon Mallee NE Metro S Metro WC Metro ICS of patient residence Lung cancer standardised incidence rate Victorian Average Age standardised incidence rate per 100, Barwon Gippsland Grampians Hume Loddon Mallee NE Metro S Metro WC Metro ICS of patient residence Source: VCR 2012
14 Lung cancer (C33-C34) relative 5-year survival by ICS ( ) survival percentage Barwon Gippsland Grampians Hume Loddon-Mallee NE Metro Southern Metro Western and Central Metro p= 0.35 ICS Source: VCR Cancer Survival 2012
15 Lung cancer (C33-C34) absolute survival time by region of residence All patients - VCR only dataset Kaplan-Meier estimates Region of residence Regional Metro Survival time (months) Number at risk Regional Metro Source: VCR January December 2012 Log rank p= Source: VCR January 2008-December 2012
16 The lung cancer population at presentation
17 Comparison over time *VCR January 2008 December 2012 #Death certificate only excluded (4%) VCR* n= 10, POC study n= 841 Gender male 60% (6,097) 63% (531) Age median 71 (10-99) 72 (30-94) No tissue diagnosis # 13% (1,328) 10% (85) With tissue diagnosis: Of NSCLC cases: SCLC 11% (1,151) 13% (101) NSCLC 76% (7,755) 78% (655) Adenocarcinoma 44% (3,386) 40% (261) Squamous cell 24% (1,840) 23% (152) Large cell 5% (418) 13% (82) Other / unspecified 27% (2,111) 25% (160)
18 2003 POC study: smoking Smoking (data available for 95% cases) - never 63 (8%) - past 458 (57%) - current 278 (35%) 71% of non-smokers are female - Female lung cancer 4.5% non-smokers - Male lung cancer 3.3% non-smokers (p<0.001) Previous smokers ceased median 12 years earlier Tobacco exposure in smokers - Median 50 pack years - Females 37 PY vs Males 52 PY (p<0.001)
19 Lung cancer (C33-C34) gender distribution by ICS n=10,234 Percentage of males in region By region of residence Barwon Gippsland Grampians Hume Loddon Mallee NEMICS SMICS WCMICS % Source: VAED/VCR January December 2012 Pearson's 2 : p=0.29
20 Lung cancer (C33-C34) place of birth by ICS n=10,234 Percentage born in Australia By region of residence Barwon Gippsland Grampians Hume Loddon Mallee NEMICS SMICS WCMICS % Source: VAED January June 2013 Pearson's 2 : p<0.01
21 2003 POC study: stage distribution For NSCLC (n=602) - Stage I 107 (18%) - Stage II 30 (5%) - Stage III 156 (26%) - IIIA 71 (12%) - IIIB 85 (14%) - Stage IV 311 (52%)
22 Lung cancer (C33-C34) cases with coded distant metastases n=10,234 Metastases recoded within four weeks of diagnosis By region of residence Barwon Gippsland Grampians Hume Loddon Mallee NEMICS SMICS WCMICS % Source: VAED/VCR January June 2013 Pearson's 2 : p<0.001 * Hume data limitation
23 Tissue diagnosis
24 Lung cancer (C33-C34) with tissue diagnosis by age group Percentage with tissue diagnosis By age group % Source: VCR January December 2012 Pearson's 2 : p<0.001
25 Lung cancer (C33-C34) with tissue diagnosis by year of diagnosis Percentage with tissue diagnosis By year of diagnosis % Source: VCR January December 2012 Test of independence: p<0.001 Test of trend: p=0.23
26 Lung cancer (C33-C34) with tissue diagnosis by ICS of residence Adjusted odds of having a tissue diagnosis By region of residence, compared to mean ICS OR (95% CI) NEMICS SMICS WCMICS Barwon Gippsland Grampians Hume Loddon 1.15 (1.01, 1.32) 0.93 (0.82, 1.04) 1.16 (0.99, 1.36) 1.54 (1.17, 2.03) 0.67 (0.53, 0.84) 0.87 (0.65, 1.17) 0.86 (0.66, 1.12) 0.89 (0.70, 1.14) Source: VCR Jan Dec Less dx More dx Adjusted for age, gender and country of birth Not adjusted for stage
27 Timeliness of diagnosis and treatment
28 Source: Victorian Lung Cancer Registry (VLCR) July June 2013 Source: Victorian Lung Cancer Registry (VLCR) 1/7/ /6/2013
29 Process Results: Timeline Diagnosis to first treatment QI 2: Percentage of patients where time from diagnosis date to first treatment date is less than 14 days Source: VLCR July June 2013
30 Timeliness of diagnosis & treatment SMICS Referral Interval Target times audit: A medical record audit, n = 98 Results: - Diagnosis within 28 days 71% (53) (no information - 24 cases) - Initiated first treatment within 14 days 48% (39) (no information - 17 cases )
31 Key challenges to timely care No priority triage Delay in receiving Incorrect location 2-4 week delay EGFR testing Bronchoscopy VATS3-4 week d EBUS Referral REFERRAL Specialist SPECIALIST Referral content Absent radiology Access Variation in staging Identification of responsible clinician Multiple referrals Accountability Pathology turnaround No palliative care ENSUING SPECIALIST Referral to Diagnosis 28D Diagnostic / staging tests Lung MDT TREATMENT Specialist SPECIALIST Inappropriate referral Delay EGFR testing Preconception re efficacy of treatment Preconception re curability Limited CDU or RT capacity Wait on next MDT Palliative delays Diagnosis to Treatment 14D TREATMENT Treatment Referral to First Treatment 42D
32 Treatment planning: Multidisciplinary team model of care
33 Integrated Cancer Services (ICS) & Lung MDM Locations Loddon Mallee ICS Mildura Base Hospital Thoracic & UGI MDM Bendigo Health Thoracic & UGI MDM Goulburn Valley Health Shepparton Lung MDM Albury Wodonga Lung MDM Grampians ICS Hume ICS Barwon South Western ICS Gippsland ICS Peter Mac Cancer Centre Lung MDM Epworth (Richmond) Lung MDM Ballarat Health Thoracic MDMs Barwon Health Lung MDM Central Gippsland HS Sale Lung MDM St Vincent s Health Lung MDM The Austin Lung MDM Ballarat SJOG Thoracic MDMs Western Hospital (Footscray) Lung MDM Royal Melbourne Hospital Lung MDM The Alfred Lung MDM Western Central MICS North Eastern MICS Southern MICS Frankston Hospital Lung MDM Eastern Health (Box Hill) Lung MDM Cabrini Lung MDM Monash Medical Centre Clayton Lung MDM
34 Multidisciplinary treatment planning for newly diagnosed lung patients % Percentage with evidence in medical record 80% 60% 40% 20% 62% 2011 Regional ICS 2012 Regional ICS 2013 Regional ICS 2011 Metrol ICS 2012 Metro ICS 2013 Metro ICS Victoria Average 0% Barwon n = Gippsland n = 8-19 Grampians n = 2-33 Hume n = Loddon Mallee n = 9-21 NE Metro n = S Metro n = W Metro n = ICS of MDM 2003 POC study: MDM discussion 29% Source: DH Audit
35 2003 POC study: case discussion at MDM Cases discussed at MDM were more likely: - Younger: 69yr vs 73yr (p<0.001) - Treated with curative intent: 44% vs 22% (p<0.001) - Better PS 0-1: 69% vs 55% (p<0.001) - Early stage disease: 31% vs 21% (p=0.004) - More likely to receive treatment: 82% vs 71% (p=0.004) Had improved survival: 10.8 vs 5.5mths (p <0.001)
36 2003 POC study: MDM discussion and patient outcomes As some patients may have died too quickly for a MDM discussion to be held, a landmark analysis was conducted for patients surviving at least 2 mths: - Improved survival 13.3mths vs 9.3 mths p<0.001 On multivariate analysis, including all significant variables, MDM discussion an independent prognostic factor for survival: - For all lung cancer p= For NSCLC p=0.005
37 Staging
38 2003 POC study Before curative: POC 2003 study: 43% surgery 78% documented PET scan radiotherapy 84% Source: Source: VLCR Victorian July Lung June Cancer 2013 Registry (VLCR) 1/7/ /6/2013
39 Tissue diagnosis Source: VLCR July June 2013 Source: Victorian Lung Cancer Registry (VLCR) 1/7/ /6/2013
40 Staging in MDM documentation for cases discussed at MDM ( ) 100% Percentage with evidence of disease staging in MDT recommendations 80% 60% 40% 20% 73% 2011 Regional ICS 2012 Regional ICS 2013 Regional ICS 2011 Metro ICS 2012 Metro ICS 2013 Metro ICS Victoria Average 0% Barwon n = 7-17 Gippsland n = 6-14 Grampians n = 0-18 Hume n = 0-11 Loddon Mallee n = 8-15 ICS of MDM NE Metro n = S Metro n = W Metro n = Source: DH audit Sampling from VCR
41 Treatment: Surgery in NSCLC
42 Major lung surgery from VAED Pneumonectomy Lobectomy of lung Partial resection of lung Other excision procedures on lung or pleura
43 Major lung cancer surgery in NSCLC by ICS of residence n= 2,035 Percentage of NSCLC who have had major surgery By region of residence Barwon Gippsland Grampians Hume Loddon Mallee NEMICS SMICS WCMICS % Source: VAED January June 2013 Pearson's 2 : p=0.056 * Hume data limitation
44 Major lung cancer surgery in NSCLC by ICS of residence n= 2,035 Adjusted odds of having major surgery for NSCLC By region of residence, compared to mean ICS OR (95% CI) NEMICS SMICS WCMICS Barwon Gippsland Grampians Hume Loddon 1.16 (1.04, 1.30) 1.16 (1.05, 1.28) 1.07 (0.95, 1.21) 0.97 (0.80, 1.19) 0.92 (0.73, 1.16) 0.80 (0.61, 1.04) 0.96 (0.75, 1.23) 0.96 (0.77, 1.19) Source: VAED January June Less Sx More Sx Adjusted for age, gender and country of birth Not adjusted for stage
45 Ratio of NSCLC lobectomy: pneumonectomy by ICS of residence n=1277 Barwon 0.15 Gippsland 0.08 Grampians 0.10 Hume 0.07 Loddon Mallee 0.09 NEMICS 0.11 SMICS 0.14 WCMICS 0.09 Ratio of lobectomy to pneumonectomy (NSCLC) By region of residence % Source: VAED January June 2013 Pearson's 2 : p=0.638 Lobectomy Pneumonectomy * Hume data limitation
46 Ratio of NSCLC lobectomy: pneumonectomy in by ICS of treatment n=1277 Barwon 0.09 Gippsland 0.00 Grampians 0.00 Hume 0.00 Loddon Mallee 0.04 NEMICS 0.11 SMICS 0.11 WCMICS 0.13 Ratio of lobectomy to pneumonectomy for NSCLC By region of treatment % Source: VAED January June 2013 Pearson's 2 : p=0.31 Lobectomy Pneumonectomy * Hume data limitation
47 Lung cancer major surgery: ICS of treatment by ICS of residence ICS of residence at first admission ICS of treatment NEMICS (n=416) SMICS (n=484) WCMICS (n=347) Barwon (n=131) Gippsland (n=98) Grampians (n=69) Hume (n=92) Loddon (n=117) Interstate (n=399) Total (n=2153) NEMICS SMICS WCMICS Barwon Gippsland 0 Grampians Hume 0 Loddon PICS 1 1
48 Lung cancer major surgery: annual volume by health service 2012 volume by campus Number of procedures Public Private Regional Metro Source: VAED 2012 For partial resection, lobectomy & pneumonectomy procedures
49 Surgical NSCLC patient survival time by regional vs metro Surgical patients with NSCLC living in regional areas Kaplan-Meier estimates Number at risk Regional Metro Region of surgical treatment Regional Metro Survival time (months) Source: VCR/VAED January December 2012 Log rank p=0.55
50 30 day mortality following major lung surgery in NSCLC ICS By ICS of residence n=1 615, p= 0.84 By ICS of treatment n=2 035, p=0.3 Barwon 4% (5) 5% (6) Gippsland 1% (1) 0 Grampians 3% (3) 5% (3) Hume 1% (1) 1% (4) Loddon-Malle 2% (2) 0 NEMICS 2% (9) 2% (10) SMICS 2% (9) 3% (16) WCMICS 3% (9) 2% (14) Source: VCR/VAED January 2008-December 2012
51 Chemotherapy in NSCLC
52 Chemotherapy within 90 days of major lung surgery n=2035 Percentage with adjuvant chemo in NSCLC By region of residence Barwon Gippsland Grampians Hume Loddon Mallee NEMICS SMICS WCMICS % Source: VAED January June 2013 Pearson's 2 : p<0.001 * Hume data limitation
53 Chemotherapy within 90 days of lobectomy / pneumonectomy n=1277 Percentage of NSCLC with adjuvant chemo Following lobectomy or pneumonectomy By region of residence Barwon Gippsland Grampians Hume Loddon Mallee NEMICS SMICS WCMICS % Source: VAED January June 2013 Pearson's 2 : p=0.001 * Hume data limitation
54 Chemotherapy within 90 days of surgery Adjuvant chemo post lobectomy/pneumonectomy By region of residence, compared to mean ICS OR (95% CI) NEMICS SMICS WCMICS Barwon Gippsland Grampians Hume Loddon 1.37 (1.07, 1.76) 0.98 (0.78, 1.24) 0.48 (0.33, 0.69) 0.87 (0.54, 1.39) 1.53 (0.87, 2.66) 0.42 (0.16, 1.09) 0.94 (0.52, 1.71) 1.41 (0.82, 2.43) Source: VAED January June No AC AC Adjusted for age, gender and country of birth Not adjusted for stage
55 Radiotherapy utilisation for lung cancer
56 Utilisation rates by ICS of residence for lung cancer in Percentage of incidence Number of cases receiving RT S Metro 50% 718 NE Metro 48% 581 WC Metro 51% 499 Metro total 49% 1798 Barwon 45% 226 Gippsland 55% 174 Grampians 34% 131 Hume 40% 141 Loddon Mallee 50% 213 Regional total 46% 885 Victorian total 48% 2683 Source: Victorian Radiotherapy Minimum Dataset (VRMDS) CCORE estimate for lung cancer 77%
57 Curative intent RT in Lung cancer % Curative versus palliative intent RT 80% % patients receiving RT 60% 40% % palliative % curative 20% 0% 10% 26% 26% 31% 28% 25% 25% 25% Barwon SW Gippsland Grampians Hume Loddon Mallee ICS of patient residence North Eastern Southern Western Central Source: Victorian Radiotherapy Minimum Data Set (VRMDS)
58 Supportive Care and Palliative Care
59 Source: VLCR Source: July Victorian June Lung 2013 Cancer Registry (VLCR) 1/7/ /6/2013
60 Supportive care needs screening 100% Percentage with evidence of supportive care screening 80% 60% 40% 20% 2011 Regional ICS 2012 Regional ICS 2013 Regional ICS 2011 Metro ICS 2012 Metro ICS 2013 Metro ICS Victoria Average 0% Barwon n = Gippsland n = 8-19 Grampians n = 2-33 Hume n = Loddon Mallee = 9-21 n NE Metro n = S Metro n = W Metro n = Source: DH audit Sampling from VCR
61 Process Results: Palliative care access QI 22: Percentage of patients with stage IV NSCLC referred to palliative care, where time between date of diagnosis and date of referral is less than or equal to 56 days. Source: VLCR July June 2013
62 Conclusions Lung cancer survival trending upwards Significant variation in 5 year survival regional vs metro Some difference in the likelihood of receiving a tissue diagnosis across ICS Some data suggests timeliness of diagnosis and treatment is an issue Low volumes of major lung surgery in a number of health services
63 Conclusions cont. Lung MDM case discussions could improve 63% for the state There is variation in rates of adjuvant chemo across ICS Overall under-utilisation of radiation therapy Low and variable uptake of formalised supportive care screening
64 Acknowledgments Working party Project team David Ball (chair) NEMICS SMICS Andreas Baisch Mirela Matthews Gerry Largey Richard De Boer Mandy Byrne Michael MacManus Megan Dendle Cancer Council Vic Paul Mitchell Barbara Morisson Rachel Whiffen Gary Richardson Rob Stirling Monash University Big thanks for data Craig Underhill Myra McGuinness VCLR: Rob Stirling Gavin Wright Rory Wolfe DH: Kathryn Whitfield Jackie Yoong VCR: Vicky Thursfield & Georgina Marr
Colorectal cancer care in Victoria ( )
Colorectal cancer care in Victoria (2011-2015) Mr Brian Hodgkins Please note: Some changes have been made for the purpose of publication Colorectal Cancer Summit working party Chairs: Geoff Chong Brian
Head & Neck Cancer Care in Victoria
Head & Neck Cancer Care in Victoria Towards optimal care Mr Stephen Tudge Head & Neck Cancers Summit working party Chairs: Mr Stephen Tudge Members: Dr Alam (Muhammad) Alamgeer Dr Stephen Brown Mr David
Regional Inequalities in Access To Palliative Care Across Victoria
Regional Inequalities in Access To Across Victoria At least 10,000 Victorians who die this year will miss out on needed access to palliative care. They do not have access to palliative care when and where
Patient Outcomes in Palliative Care for Victoria
Patient Outcomes in Palliative Care for Victoria July to December 215 PCOC is a national palliative care project funded by the Australian Government Department of Health The Palliative Care Outcomes Collaboration
Victorian Cancer Performance Monitoring Framework (VCPMF)
Victorian Cancer Performance Monitoring Framework (VCPMF) Phase II Pilot Cancer Performance Indicator Results 2013 Data December 2016 Cancer Performance Indicator Results 2013 Data 1 Contents Invitation
Cancer Services Performance Indicators. Round Report
Cancer Services Performance Indicators Round 1 2015 Report To receive this publication in an accessible format phone (03) 9096 2136, using the National Relay Service 13 36 77 if required, or email cancerplanning@dhhs.vic.gov.au
Cancer Service Performance Indicators Round 1 Report. Integrated Cancer Services. January Department of Health
Cancer Service Performance Indicators 2013 Round 1 Report Integrated Cancer Services January 2014 Department of Health For further information please contact Kathryn Whitfield, Cancer Reform Manager Tel
Phase II Malnutrition in Victorian Cancer Services: summary report
Phase II Malnutrition in Victorian Cancer Services: summary report Learnings and recommendations from the statewide and local health services projects 2013 2014 Phase II Malnutrition in Victorian Cancer
Department of Health & Human Services
Department of Health & Human Services Cancer Services Performance Indicators Round 1 2014 Report Department of Health & Human Services For further information please contact Kathryn Whitfield, Acting Manager,
A situation analysis
Dietitian involvement in the care of upper gastro-intestinal cancer patients: A situation analysis Prepared by: Wendy Wild Prepared for: Athina Georgiou, General Manager Allied Health, Southern Health
Dr. Andres Wiernik. Lung Cancer
Dr. Andres Wiernik Lung Cancer Lung Cancer Facts - Demographics World Incidence: 1 8 million / year World Mortality: 1 6 million / year 5-year survival rates vary from 4 17% depending on stage and regional
Cancer Services Performance Indicators. Data Collection Method 2014
Cancer Services Performance Indicators Data Collection Method 2014 Contents 1. Introduction... 4 2. Data collection period... 5 3. Patient sample... 5 3.1 Identification of the patient sample... 5 3.2
Slide 1. Slide 2. Slide 3. Investigation and management of lung cancer Robert Rintoul. Epidemiology. Risk factors/aetiology
Slide 1 Investigation and management of lung cancer Robert Rintoul Department of Thoracic Oncology Papworth Hospital Slide 2 Epidemiology Second most common cancer in the UK (after breast). 38 000 new
NLCA annual report analysis 2017 (for the population of 2016)
NLCA annual report analysis 2017 (for the population of 2016) Overview Patient level data for England, Wales and Guernsey were analysed together, with Guernsey considered as an English trust to simplify
Patient Pathway Mapping Project
West Hume Cancer Network Patient Pathway Mapping Project 2011-2012 Head and Neck tumour stream: Larynx, pharynx and oral cancer December 2012 Page 1 of 96 TABLE OF CONTENTS 1. EXECUTIVE SUMMARY... 7 2.
Prostate Cancer Registry: an update
Prostate Cancer Registry: an update Sue Evans on behalf of the PCR Steering Committee Registry Special Interest Group 10 August 2012 Acknowledgements PCR Project coordinators Julie Wood (metro) Joanne
Patient Pathway Mapping Project
Border/East Hume Cancer Network Patient Pathway Mapping Project Lung tumour stream: non-small cell lung cancer July 2013 Lung PPM Report Page 1 of 102 TABLE OF CONTENTS 1. EXECUTIVE SUMMARY... 6 2. AIM
Department of Health (DOH)
The Victorian Dysphagia Screening Project Department of Health (DOH) Victorian Stroke Clinical Network O ur tools. Impact of Dysphagia Aspiration Pneumonia Malnutrition Dehydration Increased LOS Increased
Care of lung cancer patients in Northern Ireland diagnosed 2014
Cancer Registry page 1 Care of lung cancer patients in Northern Ireland diagnosed 2014 (with comparisons to findings reported 1996, 2001 and 2006 and in the National Lung Cancer Audit for patients diagnosed
Diagnostic Audiology Centres. Diagnostic Audiology Centres for VIHSP referred babies
Diagnostic Audiology Centres There are a number of diagnostic audiology centres which provide services for newborns in Victoria. This list is split into two sections. Section A (coloured blue) details
Charles Mulligan, MD, FACS, FCCP 26 March 2015
Charles Mulligan, MD, FACS, FCCP 26 March 2015 Review lung cancer statistics Review the risk factors Discuss presentation and staging Discuss treatment options and outcomes Discuss the status of screening
SE SCOTLAND CANCER NETWORK PROSPECTIVE CANCER AUDIT LUNG CANCER REPORT ON PATIENTS DIAGNOSED 1 JANUARY 31 DECEMBER 2009
SE SCOTLAND CANCER NETWORK PROSPECTIVE CANCER AUDIT LUNG CANCER REPORT ON PATIENTS DIAGNOSED 1 JANUARY 31 DECEMBER 2009 Dr Ron Fergusson SCAN Lead Lung Cancer Clinician Dr Colin Selby Dr Jakki Faccenda
Resources for health professionals (3) Risk Factors (5) Initial investigations (8) Red Flag (9) Diagnosis and staging (12)
Lung Cancer Care map information (1) Resources for patients, families and carers (2) Resources for health professionals (3) Aboriginal and Torres Strait Islander Health (4) Risk Factors (5) Red Flag (7)
Closing the Gap: Advancing Indigenous Eye Health Across Diverse Regions and Systems
Closing the Gap: Advancing Indigenous Eye Health Across Diverse Regions and Systems Jatkar U, Anjou M, Schubert N, Roberts P, Taylor HR Uma Jatkar, Indigenous Eye Health National Rural Health Alliance
Using Cancer Registration and MDT Data to Provide Information on Recurrent and Metastatic Breast Cancer
Using Cancer Registration and MDT Data to Provide Information on Recurrent and Metastatic Breast Cancer Dr Gill Lawrence, WM KIT, on behalf of Breast SSCRG Cancer Outcomes Conference, Brighton, June 2013
Audit Report. Lung Cancer Quality Performance Indicators. Patients diagnosed January December Published: November 2017
Lung Cancer Managed Clinical Network Audit Report Lung Cancer Quality Performance Indicators Patients diagnosed January December 2016 Published: November 2017 Hardy Remmen NOSCAN Lung Cancer MCN Clinical
How can we facilitate cross-boundary working in Greater Manchester?
How can we facilitate cross-boundary working in Greater Manchester? Emma Halkyard Nurse Clinician Cross boundary working: where are we now? Our patients are complex Our pathways are complex Our treatments
Report to Waikato Medical Research Foundation
Report to Waikato Medical Research Foundation Understanding the importance of tumour biology and socio-demographic difference in cancer stage at diagnosis using the Midland Lung Cancer Register Ross Lawrenson
Audit Report. Lung Cancer Quality Performance Indicators. Patients diagnosed April 2014 March Published: May 2016
NORTH OF SCOTLAND PLANNING GROUP Lung Cancer Managed Clinical Network Audit Report Lung Cancer Quality Performance Indicators Patients diagnosed April 2014 March 2015 Published: May 2016 Mr Hardy Remmen
Ministerial Communiqué Number 6
Alcohol and Drug Treatment System Reform Ministerial Communiqué Number 6 June 2014 Completion of Recommissioning of Adult Services Recommissioning of adult non-residential alcohol and drug services is
Audit Report. Report of the 2010 Clinical Audit Data. West of Scotland Cancer Network. Lung Cancer Managed Clinical Network
West of Scotland Cancer Network Lung Cancer Managed Clinical Network Audit Report Report of the 2010 Clinical Audit Data Dr Richard Jones Consultant Clinical Oncologist MCN Clinical Lead Tracey Cole MCN
Context of Care: Lung Cancer at a Regional Cancer Centre. Skye Kinder
Context of Care: Lung Cancer at a Regional Cancer Centre Skye Kinder Introduction 372 inpatient unit beds 72 same-day acute beds 80 bed psychiatric inpatient unit 11 operating theatres Introduction Burden
Victorian Paediatric Oncology Situational Analysis & Workforce Requirements
- Victorian Paediatric Oncology Situational Analysis & Workforce Requirements 2012-2026 SUMMARY REPORT May 2013 1 Contents Executive summary...3 1. Introduction...6 2. Project method...8 2.1 Estimating
Cancer Care in the Veterans Health Administration
Cancer Care in the Veterans Health Administration Michael J Kelley, MD National Program Director for Oncology Department of Veterans Affairs Professor of Medicine Duke University Medical Center Chief,
NICE Quality Standards and COF
NICE Quality Standards and COF David Baldwin Consultant Respiratory Physician NUH Hon Senior Lecturer Nottingham University Clinical lead NICE lung cancer GL Chair NICE QS Topic Expert Group Quality Standards
Clinical Advice to Cancer Alliances for the Commissioning of the whole Lung Cancer Pathway
Clinical Advice to Cancer Alliances for the Commissioning of the whole Lung Cancer Pathway This document was produced by the Lung Cancer Clinical Expert August 2017 Document Title: Clinical Advice to Cancer
Location of cancer services and cancer support services in NEMICS region
Location of cancer services and cancer support services in NEMICS region Contents 1. Diagnostics, radiology, pathology, research, and outpatients... 2 2. Multidisciplinary meetings and cancer surgery...
Treatment of oligometastatic NSCLC
Treatment of oligometastatic NSCLC Jarosław Kużdżał Department of Thoracic Surgery Jagiellonian University Collegium Medicum, John Paul II Hospital, Cracow New idea? 14 NSCLC patients with solitary extrathoracic
Northern Suburbs Clinic for Lung Cancer (NSCLC): Targeting Lung Cancer
Northern Suburbs Clinic for Lung Cancer (NSCLC): Targeting Lung Cancer Page 1 Phuong Tran (Rad Onc) Lung Cancer Most common cause of cancer related deaths in Australia 19% of all cancer deaths Survival
Adam J. Hansen, MD UHC Thoracic Surgery
Adam J. Hansen, MD UHC Thoracic Surgery Sometimes seen on Chest X-ray (CXR) Common incidental findings on computed tomography (CT) chest and abdomen done for other reasons Most lung cancers discovered
DENTAL HEALTH SERVICES VICTORIA
DENTAL HEALTH SERVICES VICTORIA OUR ORGANISATION VALUES AND BEHAVIOURS OUR ROLE Dental Health Services Victoria (DHSV) is the lead oral health agency in Victoria. We provide oral health services through
MANAGING LUNG CANCER GP CME South Roland Meyer Respiratory Physician, Southern DHB
MANAGING LUNG CANCER GP CME South 19.8.12 Roland Meyer Respiratory Physician, Southern DHB 137R.00 137S.00 It takes years to be detectable 27 tumor doublings for 1cm Spirometry to identify those at risk
LUNG CANCER 2010 COMPARATIVE AUDIT REPORT
SOUTHEAST SCOTLAND CANCER NETWORK PROSPECTIVE CANCER AUDIT LUNG CANCER 2010 COMPARATIVE AUDIT REPORT Dr Ron Fergusson, NHS Lothian SCAN Lead Lung Cancer Clinician Dr Jakki Faccenda, NHS Borders Dr Paul
Adjuvant Chemotherapy
State-of-the-art: standard of care for resectable NSCLC Adjuvant Chemotherapy JY DOUILLARD MD PhD Professor of Medical Oncology Integrated Centers of Oncology R Gauducheau University of Nantes France Adjuvant
The Child Dental Health Survey, Victoria 1999
The Child Dental Health Survey, Victoria 1999 AIHW Dental Statistics and Research Unit The University of Adelaide in collaboration with Dental Health Services Victoria AIHW Catalogue No. DEN 87 AIHW Dental
Making the Most of Your Cancer Registry
www.champsods.com Making the Most of Your Cancer Registry Presenter: Toni Hare, Vice President CHAMPS Oncology Data Services Picture of girl here December 11, 2009 Learning Objectives Upon completion of
Trends in hepatocellular carcinoma, Victoria, Australia,
Trends in hepatocellular carcinoma, Victoria, Australia, 2004-2013 Carville KS 1,2, Cowie BC 1-4, MacLachlan JH 1-3 1. WHO Collaborating Centre for Viral Hepatitis, The Doherty Institute 2. VIDRL, Royal
Well Women Workshops. Hume RICS Annual Report
Newsletter November 2014 Inside this issue: Well Women Workshops 1 Hume RICS Annual Report 1 Our mission is to guide and coordinate the development of cancer services and positively make a difference to
Evaluation of Cancer Outcomes Barwon South West Registry
Evaluation of Cancer Outcomes Barwon South West Registry Data Request Form Applicant details Applicant name: Position: Email: Project start date: Date: Telephone: Project completion date: Project details
Apples and pears? A comparison of two sources of national lung cancer audit data in England
ORIGINAL ARTICLE LUNG CANCER Apples and pears? A comparison of two sources of national lung cancer audit data in England Aamir Khakwani 1, Ruth H. Jack 2, Sally Vernon 3, Rosie Dickinson 4, Natasha Wood
Guidelines for timely initiation of chemotherapy
Guidelines for timely initiation of chemotherapy A proposed framework for access to medical oncology and haematology cancer clinics and chemotherapy services in Victoria Guidelines for timely initiation
Patient Outcomes in Palliative Care for South Australia
Patient Outcomes in Palliative Care for South Australia July to December 215 PCOC is a national palliative care project funded by the Australian Government Department of Health The Palliative Care Outcomes
Care of bladder cancer patients diagnosed in Northern Ireland 2010 & 2011 (Summary)
Care of bladder cancer patients diagnosed in 2010 & 2011 (Summary) Bannon, F., Ranaghan, L., & Gavin, A. (2014). Care of bladder cancer patients diagnosed in 2010 & 2011 (Summary). N. Cancer Registry,
Recent evidence regarding resection rate, specialism and survival in lung cancer in the UK
Recent evidence regarding resection rate, specialism and survival in lung cancer in the UK Dr Mick Peake Glenfield Hospital, Leicester Clinical Lead, National Cancer Intelligence Network & National Lung
Lung Cancer Update. HARMESH R NAIK, MD. February 28, 2001
Lung Cancer Update HARMESH R NAIK, MD. February 28, 2001 Progress update Prevention Screening Staging Treatment Epidemiology Estimated 169,500 new cases Estimated 157,400 deaths Second commonest cancer
LCA Lung Clinical Forum. 21 st October 2014
LCA Lung Clinical Forum 21 st October 2014 Welcome Dr Liz Sawicka Chair - LCA Lung Pathway Group Succession planning Dr Kate Haire Consultant in Public Health Medicine, LCA Commissioning Intentions for
Lung Cancer Patient Outcomes
Lung Cancer Patient Outcomes Dr Neal Navani MA MSc PhD FRCP Consultant Respiratory Physician, UCLH Clinical Senior Lecturer, UCL Lead Clinician for Lung Cancer, UCLH Co-Clinical Lead, NLCA, Royal College
National Optimal Lung Cancer Pathway
National Optimal Lung Cancer Pathway This document was produced by the Lung Clinical Expert Group 2017 Document Title: National Optimal Lung Cancer Pathway and Implementation Guide Date of issue: August
Clinical application of optimal care pathways at a regional cancer centre
Clinical application of optimal care pathways at a regional cancer centre Skye Kinder, 1 Karla Gough, 1,2 Meinir Krishnasamy, 1,3,4 1. Faculty of Medicine, Dentistry and Health Sciences, University of
Better Outcomes for Lung Cancer in Family Practice. AProf Jeff Garrett Respiratory Physician
Better Outcomes for Lung Cancer in Family Practice AProf Jeff Garrett Respiratory Physician Lung Cancer Leading cause of cancer death in NZ overall Maori have especially poor lung cancer outcomes 19% cancer
Lung Cancer: Diagnosis, Staging and Treatment
PATIENT EDUCATION patienteducation.osumc.edu Lung Cancer: Diagnosis, Staging and Treatment Cancer starts in your cells. Cells are the building blocks of your tissues. Tissues make up the organs of your
National Breast Cancer Audit next steps. Martin Lee
National Breast Cancer Audit next steps Martin Lee National Cancer Audits Current Bowel Cancer Head & Neck Cancer Lung cancer Oesophagogastric cancer New Prostate Cancer - undergoing procurement Breast
Audit Report Report of the 2011 Clinical Audit Data
Lung Cancer Managed Clinical Network Audit Report Report of the 2011 Clinical Audit Data Dr Richard Jones Consultant Clinical Oncologist MCN Clinical Lead Kevin Campbell MCN Manager Julie McMahon Information
The 7th Edition of TNM in Lung Cancer.
10th European Conference Perspectives in Lung Cancer. Brussels, March 2009. The 7th Edition of TNM in Lung Cancer. Peter Goldstraw, Consultant Thoracic Surgeon, Royal Brompton Hospital, Professor of Thoracic
Annual Report July 2013 June 2014
Annual Report July 2013 June 2014 Prepared by the Family Reconciliation Mediation Program Team September 2014 Table of Contents Introduction... 3 Staff comings and goings... 3 The FRMP Team... 4 Sector
Strengthening palliative care: Policy and strategic directions
Strengthening palliative care: Policy and strategic directions 2011 2015 4 Clinical review of area mental health services 1997-2004 Strengthening palliative care: Policy and strategic directions 2011 2015
National Optimal Lung Cancer Pathways. Dr Sadia Anwar Nottingham University Hospitals NHS Trust Clinical Lead for Lung Cancer
National Optimal Lung Cancer Pathways Dr Sadia Anwar ttingham University Hospitals NHS Trust Clinical Lead for Lung Cancer Overview How NOLCP evolved How it relates to national guidance Pathways Implementation
Indeterminate Pulmonary Nodules in Patients with Colorectal Cancer
Indeterminate Pulmonary Nodules in Patients with Colorectal Cancer Jai Sule 1, Kah Wai Cheong 2, Stella Bee 2, Bettina Lieske 2,3 1 Dept of Cardiothoracic and Vascular Surgery, University Surgical Cluster,
Staging Issues: Lung Cancer & Mesothelioma. Mick Peake Clinical Lead, NCIN Chair, Lung SSCRG
Staging Issues: Lung Cancer & Mesothelioma Mick Peake Clinical Lead, NCIN Chair, Lung SSCRG Staging systems Non-Small Cell Lung Cancer (>85%): UICC TNM v6 used until 1.1.10 transition since then to v7
Site Accreditation for Rehabilitation Medicine
Site Accreditation for Rehabilitation Medicine Last updated September 2018 Hospital State Status No. of University of Canberra Hospital ACT Accredited 4 General, Neurological, Geriatric, Community Feb
The Itracacies of Staging Patients with Suspected Lung Cancer
The Itracacies of Staging Patients with Suspected Lung Cancer Gerard A. Silvestri, MD,MS, FCCP Professor of Medicine Medical University of South Carolina Charleston, SC silvestri@musc.edu Staging Lung
Targeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
Report prepared on behalf of the Scottish Head and Neck Cancer Networks by the WoSCAN Information Team
Scottish Head and Neck Cancer Networks Report of the 2011 Clinical Audit Data Presented at the National Head and Neck Cancer Education Day 26th October 2012 Report prepared on behalf of the Scottish Head
North of Scotland Cancer Network Clinical Management Guideline for Non Small Cell Lung Cancer
THIS DOCUMENT IS North of Scotland Cancer Network Clinical Management Guideline for Non Small Cell Lung Cancer [Based on WOSCAN NSCLC CMG with further extensive consultation within NOSCAN] UNCONTROLLED
Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010
LSU HEALTH SCIENCES CENTER NSCLC Guidelines Feist-Weiller Cancer Center Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010 Initial Evaluation/Intervention: 1. Pathology Review 2. History and Physical
Lung Cancer Quality Performance Indicators
Publication Report Lung Cancer Quality Performance Indicators Patients diagnosed during April 2013 to December 2015 Publication date 28 th February 2017 RESTRICTED STATISTICS Release embargoed until Tuesday
Lung Cancer. Current Therapy JEREMIAH MARTIN MBBCh FRCSI MSCRD
Lung Cancer Current Therapy JEREMIAH MARTIN MBBCh FRCSI MSCRD Objectives Describe risk factors, early detection & work-up of lung cancer. Define the role of modern treatment options, minimally invasive
Lung Cancer in Women: A Different Disease? James J. Stark, MD, FACP
Lung Cancer in Women: A Different Disease? James J. Stark, MD, FACP Medical Director, Cancer Program and Director of Palliative Care Maryview Medical Center Professor of Medicine Eastern Virginia Medical
LONG-TERM SURGICAL OUTCOMES OF 1018 PATIENTS WITH EARLY STAGE NSCLC IN ACOSOG Z0030 (ALLIANCE) TRIAL
LONG-TERM SURGICAL OUTCOMES OF 1018 PATIENTS WITH EARLY STAGE NSCLC IN ACOSOG Z0030 (ALLIANCE) TRIAL Stacey Su, MD; Walter J. Scott, MD; Mark S. Allen, MD; Gail E. Darling, MD; Paul A. Decker, MS; Robert
Temporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008
Special Report Temporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008 Matthew B. Schabath, PhD, Zachary J. Thompson, PhD,
23/04/2015. Recent advances in Melanoma and Non Melanoma Skin Cancer
Recent advances in and Non Skin Cancer Rodney Sinclair Professor of Dermatology University of Melbourne & Epworth Hospital 86.5% increase 120% increase 37.5% increase 1 To ascertain incidence of NMSC De
2018 Participation Pack Supporting families in your local community
TO HELP FAMILIES WHO HAVE A CHILD WITH A LIFE-THREATENING CONDITION 2018 Participation Pack Supporting families in your local community Get involved in the Very Special Kids Piggy Bank Appeal Most of us
The effect of surgeon volume on procedure selection in non-small cell lung cancer surgeries. Dr. Christian Finley MD MPH FRCSC McMaster University
The effect of surgeon volume on procedure selection in non-small cell lung cancer surgeries Dr. Christian Finley MD MPH FRCSC McMaster University Disclosures I have no conflict of interest disclosures
Agreement between medical record and ICD-10-AM coding of mental health, alcohol and drug conditions in trauma patients
MONASH PUBLIC HEALTH & PREVENTIVE MEDICINE Agreement between medical record and ICD-10-AM coding of mental health, alcohol and drug conditions in trauma patients Tu Quan Nguyen AIPN Conference November
Supportive Care Audit NEMICS Region
Supportive Care Audit 2013-2014 NEMICS Region Melissa Shand Service Improvement Facilitator NEMICS November 2015 Acknowledgments Mandy Byrne NEMICS Cancer and Data Information Analyst Page 2 of 32 Table
MDT IMPROVEMENT PROJECT. Professor Muntzer Mughal, UCLH
MDT IMPROVEMENT PROJECT Professor Muntzer Mughal, UCLH 1995..assessment and management of rare cancers in multidisciplinary teams.. 2000 the care of all patients with cancer should be formally reviewed
Shared Care Pathway for Soft Tissue Sarcomas Presenting to Site Specialised MDTs Lung /chest wall sarcomas incl. pulmonary metastatectomy Version 2
Shared Care Pathway for Soft Tissue Sarcomas Presenting to Site Specialised MDTs Lung /chest wall sarcomas incl. pulmonary metastatectomy Version 2 Background Sarcomas that arise in the lung de novo are
BSWRICS Supportive Care Strategic Plan Supporting BSWRICS Strategic Plan
BSWRICS Supportive Care Strategic Plan 2009 2012 Supporting BSWRICS Strategic Plan 2009-2012 1 Contents: Introduction 3 Background 4 Supportive Care Environment 5 Policy Environment 8 BSWRICS Supportive
OESOPHAGO-GASTRIC CANCER 2016
SOUTH EAST SCOTLAND CANCER NETWORK PROSPECTIVE CANCER AUDIT OESOPHAGO-GASTRIC CANCER 2016 COMPARATIVE AUDIT REPORT Mr Peter Lamb SCAN Lead Upper GI Cancer Clinician Dr Jonathan Fletcher, Consultant Physician,
Epidemiology, aetiology and the patient pathway in oesophageal and pancreatic cancers
Epidemiology, aetiology and the patient pathway in oesophageal and pancreatic cancers Dr Ian Chau Consultant Medical Oncologist Women's cancers Breast cancer introduction 3 What profession are you in?
Patient Outcomes in Palliative Care for NSW and ACT
Patient Outcomes in Palliative Care for NSW and ACT July to December 215 PCOC is a national palliative care project funded by the Australian Government Department of Health The Palliative Care Outcomes
An Update: Lung Cancer
An Update: Lung Cancer Andy Barlow Consultant in Respiratory Medicine Lead Clinician for Lung Cancer (West Herts Hospitals NHS Trust) Lead for EBUS-Harefield Hospital (RB&HFT) Summary Lung cancer epidemiology
Joint replacement reviews conducted by physiotherapists Bernarda Cavka Advanced Practice Physiotherapist The Royal Melbourne Hospital
Joint replacement reviews conducted by physiotherapists Bernarda Cavka Advanced Practice Physiotherapist The Royal Melbourne Hospital 2014 The Quantum Leap The Royal Melbourne Hospital (RMH) One of two
Prognostic Factors for Survival of Stage IB Upper Lobe Non-small Cell Lung Cancer Patients: A Retrospective Study in Shanghai, China
www.springerlink.com Chin J Cancer Res 23(4):265 270, 2011 265 Original Article Prognostic Factors for Survival of Stage IB Upper Lobe Non-small Cell Lung Cancer Patients: A Retrospective Study in Shanghai,
Guide to Understanding Lung Cancer
Guide to Understanding Lung Cancer Lung cancer is the second most common cancer overall for men and women in the U.S., with an estimated 222,500 new cases in 2017. However, lung cancer is the most common
Gymnastics Victoria Regionalisation Development Strategy Project Version 2 Click Here to view Version 1
Gymnastics Victoria Regionalisation Development Strategy Project Version Click Here to view Version 1 First Step Gymnastics Victoria consulted key stakeholders, including Technical Committees and Clubs
Report on Feedback from Victorian Palliative Care Services. Capacity to meet demand, resources requirements and priorities.
Report on Feedback from Victorian Palliative Care Services Capacity to meet demand, resources requirements and priorities May 2017 Approved for release by the PCV Board. Palliative Care Victoria wishes
Building an eye care program with Aboriginal communities in Victoria a partnership approach
Building an eye care program with Aboriginal communities in Victoria a partnership approach Genevieve Napper 1 and Cheryl Vickery 1 Kulan Barney 2, Jimi Peters 2, Mitchell Anjou 3, Tim Fricke 1,4, Jonathan
Complete surgical excision remains the greatest potential
ORIGINAL ARTICLE Wedge Resection for Non-small Cell Lung Cancer in Patients with Pulmonary Insufficiency: Prospective Ten-Year Survival John P. Griffin, MD,* Charles E. Eastridge, MD, Elizabeth A. Tolley,
INTERACTIVE SESSION 2
INTERACTIVE SESSION 2 2 patients with lung metastases, with complete response after oncologic treatment - Clinical Case Presentation: Dr. Esther Casado Dr. Sergi Call - Expert Opinion: Dr. Raúl Embún Dr.